Prognostic factors after resection of locally advanced non-functional pancreatic neuroendocrine neoplasm: an analysis from the German Cancer Registry Group of the Society of German Tumor Centers

被引:6
|
作者
Abdalla, Thaer S. A. [1 ]
Klinkhammer-Schalke, Monika [2 ]
Zeissig, Sylke Ruth [2 ,3 ]
Tol, Kees Kleihues-van [2 ]
Honselmann, Kim C. [1 ]
Braun, Ruediger [1 ]
Bolm, Louisa [1 ]
Lapshyn, Hryhoriy [1 ]
Litkevych, Stanislav [1 ]
Zemskov, Sergii [4 ]
Begum, Nehara [1 ,5 ]
Kulemann, Birte [1 ]
Hummel, Richard [1 ]
Wellner, Ulrich Friedrich [1 ]
Keck, Tobias [1 ]
Deichmann, Steffen [1 ]
机构
[1] Univ Med Ctr Schleswig Holstein, Dept Surg, Ratzeburger Allee 160,Campus Lubeck, D-23564 Lubeck, Germany
[2] Network Care Qual & Res Oncol ADT, German Canc Registry Grp Soc German Tumor Ctr, Berlin, Germany
[3] Univ Wurzburg, Inst Clin Epidemiol & Biometry ICE B, Wurzburg, Germany
[4] Bogomolets Natl Med Univ, Dept Gen Surg, UA-01601 Kiev, Ukraine
[5] Johannes Wesling Klinikum Minden, Dept Surg, Minden, Germany
关键词
Pancreatic neuroendocrine neoplasms; Resection margin; Prognostic factors; Population-based analysis; GUIDELINES; DIAGNOSIS; SURVIVAL;
D O I
10.1007/s00432-023-04785-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThe available literature regarding outcome after pancreatic resection in locally advanced non-functional pNEN (LA-pNEN) is sparse. Therefore, this study evaluates the current survival outcomes and prognostic factors in after resection of LA-pNEN.Materials and methodsThis population-based analysis was derived from 17 German cancer registries from 2000 to 2019. Patients with upfront resected non-functional non-metastatic LA-pNEN were included.ResultsOut of 2776 patients with pNEN, 277 met the inclusion criteria. 137 (45%) of the patients were female. The median age was 63 +/- 18 years. Lymph node metastasis was present in 45%. G1, G2 and G3 pNEN were found in 39%, 47% and 14% of the patients, respectively. Resection of LA-pNEN resulted in favorable 3-, 5- and 10-year overall survival of 79%, 74%, and 47%. Positive resection margin was the only potentially modifiable independent prognostic factor for overall survival (HR 1.93, 95% CI 1.71-3.69, p value = 0.046), whereas tumor grade G3 (HR 5.26, 95% CI 2.09-13.25, p value < 0.001) and lymphangiosis (HR 2.35, 95% CI 1.20-4.59, p value = 0.012) were the only independent prognostic factors for disease-free survival.ConclusionResection of LA-pNEN is feasible and associated with favorable overall survival. G1 LA-pNEN with negative resection margins and absence of lymph node metastasis and lymphangiosis might be considered as cured, while those not fulfilling these criteria might be considered as a high-risk group for disease progression. Herein, negative resection margins represent the only potentially modifiable prognostic factor in LA-pNEN but seem to be influenced by tumor grade.
引用
收藏
页码:8535 / 8543
页数:9
相关论文
共 44 条
  • [21] Re: First Salvage Treatment in Patients with Advanced Germ Cell Cancer after Cisplatin-Based Chemotherapy: Analysis of a Registry of the German Testicular Cancer Study Group (GTCSG)
    Richie, Jerome P.
    JOURNAL OF UROLOGY, 2015, 193 (03): : 850 - 850
  • [22] Pathological complete response due to a prolonged time interval between preoperative chemoradiation and surgery in locally advanced rectal cancer: analysis from the German StuDoQ|Rectalcarcinoma registry
    Lichthardt, Sven
    Wagner, Johanna
    Loeb, Stefan
    Matthes, Niels
    Kastner, Caroline
    Anger, Friedrich
    Germer, Christoph-Thomas
    Wiegering, Armin
    BMC CANCER, 2020, 20 (01)
  • [23] Pathological complete response due to a prolonged time interval between preoperative chemoradiation and surgery in locally advanced rectal cancer: analysis from the German StuDoQ|Rectalcarcinoma registry
    Sven Lichthardt
    Johanna Wagner
    Stefan Löb
    Niels Matthes
    Caroline Kastner
    Friedrich Anger
    Christoph-Thomas Germer
    Armin Wiegering
    BMC Cancer, 20
  • [24] Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors
    Poettgen, Christoph
    Stuschke, Martin
    Graupner, Britta
    Theegarten, Dirk
    Gauler, Thomas
    Jendrossek, Verena
    Freitag, Lutz
    Abu Jawad, Jehad
    Gkika, Eleni
    Wohlschlaeger, Jeremias
    Welter, Stefan
    Hoiczyk, Matthias
    Schuler, Martin
    Stamatis, Georgios
    Eberhardt, Wilfried
    BMC CANCER, 2015, 15
  • [25] Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors
    Christoph Pöttgen
    Martin Stuschke
    Britta Graupner
    Dirk Theegarten
    Thomas Gauler
    Verena Jendrossek
    Lutz Freitag
    Jehad Abu Jawad
    Eleni Gkika
    Jeremias Wohlschlaeger
    Stefan Welter
    Matthias Hoiczyk
    Martin Schuler
    Georgios Stamatis
    Wilfried Eberhardt
    BMC Cancer, 15
  • [26] Five-year Survival Outcome of patients with synchronous oligometastatic or locally advanced Non-small cell lung cancer after definitive primary treatment: Results from the West German Cancer Center, a prospective registry trial
    Guberina, Maja
    Poettgen, Christoph
    Guberina, Nika
    Wiesweg, Marcel
    Metzenmacher, Martin
    Richlitzki, Cedric
    Hoffmann, Christian
    Eberhardt, Wilfried
    Forsting, Michael
    Herrmann, Ken
    Theegarten, Dirk
    Boeluekbas, Servet
    Aigner, Clemens
    Darwiche, Kaid
    Stuschke, Martin
    Schuler, Martin
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 128 - 128
  • [27] Analysis of prognostic factors in locally advanced and metastatic pancreatic cancer treated with gemcitabine or gemcitabine and S-1 chemotherapy using individual patient data from three randomized studies
    Nakai, Yousuke
    Okusaka, Takuji
    Ikari, Takaaki
    Isayama, Hiroyuki
    Furuse, Junji
    Ishii, Hiroshi
    Imai, Shogo
    Okamura, Shota
    Hamada, Chikuma
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [28] Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group
    Weiss, L.
    Fischer, L. E.
    Heinemann, V.
    Gieseler, F.
    Hoehler, T.
    Mayerle, J.
    Quietzsch, D.
    Reinacher-Schick, A.
    Schenk, M.
    Seipelt, G.
    Siveke, J. T.
    Stahl, M.
    Kaiser, U.
    Waldschmidt, D. T.
    Dorman, K.
    Zhang, D.
    Westphalen, C. B.
    Boeck, S.
    Haas, M.
    ESMO OPEN, 2024, 9 (04)
  • [29] Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
    Ö U Ataman
    S M Bentzen
    M I Saunders
    S Dische
    British Journal of Cancer, 2001, 85 : 1113 - 1118
  • [30] Testing for and frequency of EGFR and ALK alterations in patients with early and locally advanced non-small cell lung cancer in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315)
    Eberhardt, W. E. E.
    Thomas, M.
    Stuschke, M.
    de Wit, M.
    Seese, B.
    Spring, L.
    Andres-Pons, A.
    Janicke, M.
    Vahtrick, O.
    Ludwig, P.
    Hipper, A.
    Hoffknecht, P.
    von der Heyde, E.
    Sebastian, M.
    Groeschel, A.
    Passlick, B.
    Griesinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 10 - 11